Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer

Dow Jones received a payment from EQS/DGAP to publish this press release.

Pharnext 
Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer 
and Serge Fitoussi as Chief Medical Officer 
 
14-Jan-2019 / 17:45 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
*Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer 
and Serge Fitoussi as Chief Medical Officer* 
 
*PARIS, France, **5:45 pm**, 14 January 2019 (CET)**-*Pharnext SA 
[1]*(FR0011191287 - ALPHA)*a biopharmaceutical company pioneering a new approach 
to the development of innovative drug combinations based on big genomic data and 
artificial intelligence, today announced the appointment of Susanne Dorn, M.Sc., 
as Chief Regulatory Officer and Serge Fitoussi, M.D., M.Sc., as Chief Medical 
Officer. 
_"We are excited to welcome Susanne and Serge to our team, especially as we scale 
up our clinical and commercial activities during our transition to becoming a 
biopharmaceutical company,"_said *Daniel Cohen, M.D., Ph.D., Pharnext's 
Co-Founder and Chief Executive Officer.*_"Susanne's deep regulatory expertise and 
Serge's extensive experience in clinical development will be great assets to our 
team. We look forward to Susanne and Serge's insights as we continue to progress 
our late-stage pipeline and prepare the regulatory package in order to 
commercialize PXT3003 for Charcot-Marie-Tooth Disease type 1A (CMT1A)."_ 
Before joining Pharnext, Susanne worked as Head of Regulatory Affairs for 
Immunology and Neurology at Sanofi Genzyme in Boston, MA. Prior to that, she held 
Regulatory Affairs leadership roles at Sanofi, Halozyme Therapeutics, Amylin 
Pharmaceuticals, Pfizer and Ciba/Novartis in the U.S. and Europe, supporting 
multiple therapeutic areas. Over her 30 years of experience, Susanne provided 
regulatory leadership and support for more than 100 drugs that were marketed or 
in development and led 10 products to approval in the U.S., Europe and Japan. 
Susanne holds an M.Sc. from the Albert-Ludwigs-Universität Freiburg (Germany), a 
Diploma in Regulatory Affairs from the University of Cardiff and a Certificate in 
Management from the Open University in the U.K. 
Serge joins Pharnext from Gensight Biologics, where he served as Director of 
Medical Affairs. Previously, he worked as Global Therapeutic Area Head at 
Novartis and as Clinical Research Director in Clinical Pharmacology at Sanofi. 
Before that, Serge served as Chief Medical Officer at Tilak Healthcare and was 
also Founder and CEO of Mediscis, a CRO specialised in early-stage clinical 
trials. He has broad experience leading early- to late-stage clinical development 
and more than 25 years of experience in pharmaceutical, medical device and gene 
therapy product development, particularly in rare neurodegenerative diseases, as 
well as neuropsychiatric, respiratory, inflammation and cardiovascular diseases. 
Serge holds an M.D. and M.Sc. from the University of Paris with a Silver Medal. 
 
*About Pharnext* 
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel 
therapeutics for orphan and common neurodegenerative diseases that currently lack 
curative and/or disease-modifying treatments. Pharnext has two products in 
clinical development. PXT3003 completed an international pivotal Phase 3 trial 
with positive topline results for the treatment of Charcot-Marie-Tooth disease 
type 1A and benefits from orphan drug status in Europe and the United States. 
PXT864 has generated encouraging Phase 2 results in Alzheimer's disease. Pharnext 
has developed a new drug discovery paradigm based on big genomic data and 
artificial intelligence: PLEOTHERAPY. The Company identifies and develops 
synergic combinations of drugs called PLEODRUG offering several key 
advantages: efficacy, safety and robust intellectual property. The Company was 
founded by renowned scientists and entrepreneurs including Professor Daniel 
Cohen, a pioneer in modern genomics, and is supported by a world-class scientific 
team. 
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: 
FR0011191287). 
For more information, visit www.pharnext.com [1] 
 
*CONTACTS:* 
*Pharnext* 
Amit Kohli 
Chief Operating 
Officer 
[e-mail] 
[phone] 
*Financial           *Investor Relations    *Investor Relations 
Communication        (U.S.)*                (Europe)* 
(France)*            Stern Investor         MC Services AG 
Actifin              Relations, Inc.        Anne Hennecke 
Stéphane Ruiz        Kendra Packard         [e-mail] 
[e-mail]     [e-mail] [2] [phone] 
[phone] [phone] 
*Media Relations     *Media Relations 
(Europe)*            (U.S.)* 
Ulysse Communication RooneyPartners 
Bruno Arabian        Kate L. Barrette 
barabian             [e-mail] 
[3]@ulysse-communica [phone] 
tion.com 
[phone] 
 
Regulatory filing PDF file 
 
Document title: Pharnext Announces the Appointments of Susanne Dorn as Chief 
Regulatory Officer and Serge Fitoussi as Chief Medical Officer 
Document: http://n.eqs.com/c/fncls.ssp?u=EMGOTRQRXO [4] 
765935 14-Jan-2019 CET/CEST 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=cb3681285800d269b63272738266ab82&application_id=765935&site_id=vwd&application_name=news 
2: mailto:[e-mail] 
3: mailto:[e-mail] 
4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=32a991651e938e2cc9c9ea46ceb40a3a&application_id=765935&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

January 14, 2019 11:45 ET (16:45 GMT)